Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200451231> ?p ?o ?g. }
- W4200451231 abstract "Abstract Background Patients with Multiple Sclerosis (pwMS) treated with anti-CD20 or fingolimod showed a reduced humoral response to mRNA-based SARS-CoV-2 vaccines, while the degree of such responses is unimpaired and similar in pwMS treated with other disease modifying therapies (DMTs), or untreated. However, the nature of the SARS-CoV-2 vaccine-induced immune response is based also on cellular immunity and there is emerging evidence that anti-SARS-CoV-2 specific CD4 and CD8 T cell responses can be detected after vaccination also in patients with low antibody levels. In this study we aimed to monitor the risk of breakthrough SARS-CoV-2 infection and to identify correlates of reduced protection in frail vaccinated pwMS on different DMTs. Methods We designed a long term clinical follow-up of the CovaXiMS (Covid-19 vaccine in Multiple Sclerosis), a prospective multicenter cohort study enrolling pwMS scheduled for SARS-CoV-2 vaccination with mRNA vaccines and tested for SARS-CoV-2 antibodies before and after the second vaccine dose. These patients were followed with periodic phone calls up to a mean time of 6 months, and all the SARS-CoV-2 breakthrough infections were registered. The impact of DMTs on cumulative incidence of breakthrough Covid-19 cases was presented by Kaplan-Meier curves. A multivariable logistic model was run to assess factors associated to a higher risk of breakthrough infections. Findings 1705 pwMS (81.6% BNT162b2 and 18.4% mRNA-1273) had a full vaccination cycle (2 vaccine doses, 21/28 days apart). Of them, 1509 (88.5%) had blood assessment 4 weeks after the second vaccine dose. During follow-up, 23 breakthrough Covid-19 infections (cumulative incidence: 1.5%, SE=0.3%) were detected after a mean of 108 days after the second dose (range, 18-230). Of them, 9 were on ocrelizumab, one on rituximab, 4 on fingolimod, 6 on dimethyl-fumarate, one on teriflunomide, and 2 were untreated. Just two cases (a woman on ocrelizumab and a man on teriflunomide) required hospitalization. The probability to be infected was associated only with SARS-CoV-2 antibody levels measured after 4 weeks from the second vaccine dose (HR=0.63, p=0.007); an antibody level of 660 U/mL was calculated as the cutoff for higher risk of infection. Interpretation Our data show that the risk of breakthrough SARS-CoV-2 infections is mainly associated with reduced levels of the virus-specific humoral immune response. Funding FISM [2021/Special-Multi/001]; the Italian Ministry of Health grant ‘Progetto Z844A 5×1000’. Italian Ministry of Health: Ricerca Corrente to IRCCS Ospedale Policlinico San Martino." @default.
- W4200451231 created "2021-12-31" @default.
- W4200451231 creator A5000230349 @default.
- W4200451231 creator A5000318115 @default.
- W4200451231 creator A5004343321 @default.
- W4200451231 creator A5009280913 @default.
- W4200451231 creator A5016510324 @default.
- W4200451231 creator A5021342031 @default.
- W4200451231 creator A5023238625 @default.
- W4200451231 creator A5023656181 @default.
- W4200451231 creator A5024758852 @default.
- W4200451231 creator A5027720251 @default.
- W4200451231 creator A5028131236 @default.
- W4200451231 creator A5029744984 @default.
- W4200451231 creator A5029894629 @default.
- W4200451231 creator A5043072864 @default.
- W4200451231 creator A5044245930 @default.
- W4200451231 creator A5044776241 @default.
- W4200451231 creator A5047585580 @default.
- W4200451231 creator A5052921645 @default.
- W4200451231 creator A5054546964 @default.
- W4200451231 creator A5057395387 @default.
- W4200451231 creator A5059760300 @default.
- W4200451231 creator A5061993323 @default.
- W4200451231 creator A5062775755 @default.
- W4200451231 creator A5063188128 @default.
- W4200451231 creator A5067420465 @default.
- W4200451231 creator A5068784767 @default.
- W4200451231 creator A5069322473 @default.
- W4200451231 creator A5077537095 @default.
- W4200451231 creator A5077830592 @default.
- W4200451231 creator A5082938183 @default.
- W4200451231 creator A5083744505 @default.
- W4200451231 creator A5085934793 @default.
- W4200451231 creator A5086496784 @default.
- W4200451231 creator A5089036955 @default.
- W4200451231 creator A5089648151 @default.
- W4200451231 creator A5091674171 @default.
- W4200451231 date "2021-12-27" @default.
- W4200451231 modified "2023-10-18" @default.
- W4200451231 title "Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies" @default.
- W4200451231 cites W3028783641 @default.
- W4200451231 cites W3108610942 @default.
- W4200451231 cites W3158831599 @default.
- W4200451231 cites W3176479223 @default.
- W4200451231 cites W3184172540 @default.
- W4200451231 cites W3193948535 @default.
- W4200451231 cites W3198831432 @default.
- W4200451231 cites W3199233027 @default.
- W4200451231 cites W3200136047 @default.
- W4200451231 cites W3201177512 @default.
- W4200451231 cites W3206641838 @default.
- W4200451231 cites W3210921815 @default.
- W4200451231 cites W3213230441 @default.
- W4200451231 cites W3215972055 @default.
- W4200451231 cites W4226529687 @default.
- W4200451231 doi "https://doi.org/10.1101/2021.12.23.21268177" @default.
- W4200451231 hasPublicationYear "2021" @default.
- W4200451231 type Work @default.
- W4200451231 citedByCount "9" @default.
- W4200451231 countsByYear W42004512312022 @default.
- W4200451231 countsByYear W42004512312023 @default.
- W4200451231 crossrefType "posted-content" @default.
- W4200451231 hasAuthorship W4200451231A5000230349 @default.
- W4200451231 hasAuthorship W4200451231A5000318115 @default.
- W4200451231 hasAuthorship W4200451231A5004343321 @default.
- W4200451231 hasAuthorship W4200451231A5009280913 @default.
- W4200451231 hasAuthorship W4200451231A5016510324 @default.
- W4200451231 hasAuthorship W4200451231A5021342031 @default.
- W4200451231 hasAuthorship W4200451231A5023238625 @default.
- W4200451231 hasAuthorship W4200451231A5023656181 @default.
- W4200451231 hasAuthorship W4200451231A5024758852 @default.
- W4200451231 hasAuthorship W4200451231A5027720251 @default.
- W4200451231 hasAuthorship W4200451231A5028131236 @default.
- W4200451231 hasAuthorship W4200451231A5029744984 @default.
- W4200451231 hasAuthorship W4200451231A5029894629 @default.
- W4200451231 hasAuthorship W4200451231A5043072864 @default.
- W4200451231 hasAuthorship W4200451231A5044245930 @default.
- W4200451231 hasAuthorship W4200451231A5044776241 @default.
- W4200451231 hasAuthorship W4200451231A5047585580 @default.
- W4200451231 hasAuthorship W4200451231A5052921645 @default.
- W4200451231 hasAuthorship W4200451231A5054546964 @default.
- W4200451231 hasAuthorship W4200451231A5057395387 @default.
- W4200451231 hasAuthorship W4200451231A5059760300 @default.
- W4200451231 hasAuthorship W4200451231A5061993323 @default.
- W4200451231 hasAuthorship W4200451231A5062775755 @default.
- W4200451231 hasAuthorship W4200451231A5063188128 @default.
- W4200451231 hasAuthorship W4200451231A5067420465 @default.
- W4200451231 hasAuthorship W4200451231A5068784767 @default.
- W4200451231 hasAuthorship W4200451231A5069322473 @default.
- W4200451231 hasAuthorship W4200451231A5077537095 @default.
- W4200451231 hasAuthorship W4200451231A5077830592 @default.
- W4200451231 hasAuthorship W4200451231A5082938183 @default.
- W4200451231 hasAuthorship W4200451231A5083744505 @default.
- W4200451231 hasAuthorship W4200451231A5085934793 @default.
- W4200451231 hasAuthorship W4200451231A5086496784 @default.
- W4200451231 hasAuthorship W4200451231A5089036955 @default.
- W4200451231 hasAuthorship W4200451231A5089648151 @default.
- W4200451231 hasAuthorship W4200451231A5091674171 @default.
- W4200451231 hasBestOaLocation W42004512311 @default.